In our study, we evaluated 10 SNPs located in the SLCO1B1, SLCO1B3, ABCB1, and NR1I2 genes as genetic determinants of RIF PK, as well as investigated the possible role of these polymorphisms in the development of anti-TB treatment-related hepatotoxicity since these genes and their encoded products are recognized as being of pharmacogenetic importance. The gene discussed is NR1I2; the disease is tuberculosis.